TELO GENOMICS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.17 CAD | -5.56% |
|
0.00% | -15.00% |
| Apr. 10 | Telo Genomics Receives Accreditation from College of American Pathologists | MT |
| Apr. 10 | Telo Genomics Corp. Receives Accreditation from College of American Pathologists | CI |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 10 | 1.996 | 9.89 | 25.65 | 21.27 | 20.99 |
| Enterprise Value (EV) 1 | 9.935 | 2.256 | 9.009 | 22.05 | 18.62 | 18.35 |
| P/E ratio | -1.97 x | -1.85 x | -5.78 x | -21.9 x | -9.95 x | -6.29 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -2.22 x | -2.32 x | -7.23 x | -18.5 x | -9.09 x | -6.6 x |
| EV / FCF | -5.52 x | 30.1 x | -7.85 x | -26.3 x | -18.1 x | -11.3 x |
| FCF Yield | -18.1% | 3.32% | -12.7% | -3.8% | -5.52% | -8.85% |
| Price to Book | -31.9 x | -1.91 x | 12.8 x | 7.54 x | 8.17 x | 8.03 x |
| Nbr of stocks (in thousands) | 12,906 | 13,306 | 41,210 | 51,302 | 59,424 | 71,160 |
| Reference price 2 | 0.7750 | 0.1500 | 0.2400 | 0.5000 | 0.3580 | 0.2950 |
| Announcement Date | 11/15/18 | 10/28/19 | 10/28/20 | 10/28/21 | 9/27/22 | 10/30/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -4.484 | -0.9706 | -1.246 | -1.195 | -2.048 | -2.782 |
| EBIT 1 | -4.609 | -1.054 | -1.311 | -1.257 | -2.105 | -2.816 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -4.695 | -1.074 | -1.242 | -1.07 | -2.11 | -2.821 |
| Net income 1 | -4.695 | -1.074 | -1.242 | -1.07 | -2.11 | -2.821 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.3927 | -0.0812 | -0.0415 | -0.0228 | -0.0360 | -0.0469 |
| Free Cash Flow 1 | -1.801 | 0.075 | -1.147 | -0.839 | -1.029 | -1.625 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/15/18 | 10/28/19 | 10/28/20 | 10/28/21 | 9/27/22 | 10/30/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.26 | - | - | - | - |
| Net Cash position 1 | 0.07 | - | 0.88 | 3.6 | 2.65 | 2.64 |
| Leverage (Debt/EBITDA) | - | -0.2684 x | - | - | - | - |
| Free Cash Flow 1 | -1.8 | 0.07 | -1.15 | -0.84 | -1.03 | -1.62 |
| ROE (net income / shareholders' equity) | -491% | 158% | 921% | -48% | -67.1% | -108% |
| ROA (Net income/ Total Assets) | -163% | -190% | -114% | -31.4% | -39.4% | -61.1% |
| Assets 1 | 2.887 | 0.5646 | 1.085 | 3.41 | 5.352 | 4.616 |
| Book Value Per Share 2 | -0.0200 | -0.0800 | 0.0200 | 0.0700 | 0.0400 | 0.0400 |
| Cash Flow per Share 2 | 0.0100 | 0 | 0.0200 | 0.0700 | 0.0500 | 0.0400 |
| Capex 1 | 0.02 | - | - | 0.01 | 0.03 | 0.07 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 11/15/18 | 10/28/19 | 10/28/20 | 10/28/21 | 9/27/22 | 10/30/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -15.00% | 8.86M | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 383M |
- Stock Market
- Equities
- TELO Stock
- Financials Telo Genomics Corp.
